This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Pfizer (PFE) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, Pfizer (PFE) closed at $26.64, indicating a +1.29% shift from the previous trading day.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
by Kinjel Shah
J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.
How to Play Moderna Stock After the Recent Sales Guidance Cut
by Sundeep Ganoria
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
Should Invesco S&P 100 Equal Weight ETF (EQWL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EQWL
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Pfizer (PFE) reachead $26.41 at the closing of the latest trading day, reflecting a -1.46% change compared to its last close.
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
by Kinjel Shah
FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Pfizer (PFE) reachead $26.91 at the closing of the latest trading day, reflecting a -0.83% change compared to its last close.
Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?
by Ekta Bagri
Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and any dip in the share price can be used as a buying opportunity.
Why Pfizer (PFE) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
by Kinjel Shah
PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
by Zacks Equity Research
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.
The Zacks Analyst Blog Berkshire Hathaway, The Home Depot, Pfizer and AMREP
by Zacks Equity Research
Berkshire Hathaway, The Home Depot, Pfizer and AMREP are included in this Analyst Blog.
Pfizer (PFE) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $26.61, marking a +0.3% move from the previous day.
Top Research Reports for Berkshire Hathaway, Home Depot & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The Home Depot, Inc. (HD) and Pfizer Inc. (PFE), as well as a micro-cap stock AMREP Corporation (AXR).
Here's Why Pfizer (PFE) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 Large Drug Stocks to Keep An Eye On in the New Year
by Kinjel Shah
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.
Company News for Jan 2, 2025
by Zacks Equity Research
Companies In The News Are: X, BHVN, SGMO, PFE, BLDR.
SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate
by Zacks Equity Research
Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec.
Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $26.56, moving -0.67% from the previous trading session.
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC
by Zacks Equity Research
AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union.